GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Polyrizon Ltd
Polyrizon develops prophylactic sprays (for example, nasal sprays) to protect against viruses and allergens. Its stock price is a venture bet on the success of its platform. The chart reflects speculative interest in new disease prevention methods.
Share prices of companies in the market segment - Specialized pharma
Polyrizon is an Israeli biotech company developing protective nasal and oral gels that create a barrier against viruses and allergens. We classified it as a "Specialized Pharmaceutical" company. The chart below shows how the market values innovative preventative products.
Broad Market Index - GURU.Markets
Polyrizon is an Israeli biotech company developing protective nasal and oral sprays to prevent viral infections. It is a component of the GURU.Markets index. The chart below shows the US market. See how this company's stock compares to the US market trend.
Change in the price of a company, segment, and market as a whole per day
PLRZ - Daily change in the company's share price Polyrizon Ltd
For Polyrizon Ltd, a pharmaceutical company, daily volatility reflects sensitivity to scientific data. This metric is an important element in formulas that assess the risks and potential of companies in the innovative healthcare sector.
Daily change in the price of a set of shares in a market segment - Specialized pharma
Polyrizon develops biological gels to protect against viral and allergic particles. This is an innovative niche in pharmaceuticals with high potential, but also significant risks. The chart below shows volatility in the specialty biotech sector, which helps assess the performance of PLRZ shares.
Daily change in the price of a broad market stock, index - GURU.Markets
Polyrizon is an Israeli biotech company developing protective gels against allergens and viruses. Its shares are driven by research news. This high volatility, driven by innovation, is a significant contributor to the overall "noise" and dynamics of the stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Polyrizon Ltd
Polyrizon Ltd's year-over-year performance is a story about the development of its platform for creating protective nasal gels. Its market capitalization over the next 12 months depends entirely on progress in clinical trials. Success could offer a new way to prevent allergies and viral infections, which would be a fundamental breakthrough for the company.
Annual dynamics of market capitalization of the market segment - Specialized pharma
Polyrizon, a private biotech company, is developing a unique platform for protection against viruses and allergens. Its growth depends on successful clinical trials. Its valuation dynamics will reflect investors' faith in its science, potentially outperforming the sector if successful, but with inherent biotech risks.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Polyrizon, a biomedical company developing protective gels and sprays to prevent viral infections, has become especially relevant in light of the pandemic. Its year-over-year market capitalization reflects investors' confidence in its technology and the potential for creating a new barrier method of protection against pathogens.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Polyrizon Ltd
Polyrizon is a biopharmaceutical company. Its monthly performance is typical for the sector: it depends on progress in its scientific developments and clinical programs. News of trial results for drugs developed on its platform are the main drivers.
Monthly dynamics of market capitalization of the market segment - Specialized pharma
Polyrizon is developing prophylactic medications (such as nasal sprays) based on biogels to protect against viruses and allergens. This is an innovative approach to prevention. The company's success depends on clinical evidence of effectiveness. The pharmaceutical sector's performance will reflect the general interest in new methods of protecting against infections, especially after the pandemic.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Polyrizon is an Israeli biotech company developing protective gels for the nose and eyes against allergens and viruses. This is a niche product. The company's stock price depends on the success of clinical trials and its ability to bring the product to market. Its correlation with general market trends is minimal; it is a bet on a specific technology.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Polyrizon Ltd
Polyrizon, an Israeli biotech company developing nasal sprays for protection against viruses and allergens, operates at the intersection of science and consumer products. Its weekly stock price reflects clinical trial data and its ability to commercialize the product for the mass market.
Weekly dynamics of market capitalization of the market segment - Specialized pharma
Polyrizon is developing nasal sprays to protect against viruses and allergens. This is an innovative approach to disease prevention. The chart shows how investors are reacting to news of the product's development and potential commercialization, compared to overall trends in the specialty pharmaceutical sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Polyrizon is a biotech company developing protective nasal sprays. Its shares are a venture capital bet on science. The chart clearly demonstrates how its weekly performance can be detached from overall market movements and driven solely by domestic news.
Market capitalization of the company, segment and market as a whole
PLRZ - Market capitalization of the company Polyrizon Ltd
Polyrizon's market capitalization reflects investor sentiment for its protective gel platform. The chart reflects market confidence in its products' potential to prevent viral infections and allergic reactions by creating a barrier on mucous membranes. Its value reflects the company's early-stage scientific potential.
PLRZ - Share of the company's market capitalization Polyrizon Ltd within the market segment - Specialized pharma
Polyrizon is an Israeli biotech company developing protective gels for the nose and mouth. Its market share in the pharmaceutical sector is small, but it offers an innovative approach to prevention. Its capitalization is a bet on its platform, which creates a barrier against viruses and allergens.
Market capitalization of the market segment - Specialized pharma
This chart shows the overall value of the entire pharmaceutical sector. For Polyrizon, a small biotech company working on specialized drugs, this line represents the scale of the ocean in which it operates. The chart's fluctuations reflect global investor sentiment toward the entire industry, against which the company is trying to prove the value of its developments.
Market capitalization of all companies included in a broad market index - GURU.Markets
Polyrizon is an Israeli company developing protective gels for the nose and mouth that are supposed to prevent viral infections. Its market capitalization is based on the preventive medicine industry. This represents the market share of the "invisible mask" concept.
Book value capitalization of the company, segment and market as a whole
PLRZ - Book value capitalization of the company Polyrizon Ltd
Polyrizon develops protective gels for the nose and other mucous membranes to prevent infections. Its book value is its scientific and financial capital. It consists of platform patents and R&D funds. How has this innovative protective capital changed? The chart below shows.
PLRZ - Share of the company's book capitalization Polyrizon Ltd within the market segment - Specialized pharma
Polyrizon Ltd. develops protective biogels. Its scientific activities require a material base: a laboratory for creating and testing its formulas designed to protect against viruses and allergens. The chart shows the company's share of the physical R&D infrastructure in this specific biopharma segment.
Market segment balance sheet capitalization - Specialized pharma
Polyrizon is a biopharmaceutical company. Pharmaceuticals, as the graph shows, are knowledge- and capital-intensive. Polyrizon focuses on drug development, and its capital is its intellectual property and R&D infrastructure.
Book value of all companies included in the broad market index - GURU.Markets
Polyrizon's assets are not drugs, but a scientific platform for creating protective gel films for the nose and other mucous membranes that can prevent the penetration of viruses and allergens. The book value reflects the laboratory base for these preventative developments.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Polyrizon Ltd
Polyrizon is a biopharmaceutical company developing nasal sprays for protection against viruses and allergens. Its market value is determined by its platform and its potential to create a new category of protective products.
Market to book capitalization ratio in a market segment - Specialized pharma
Polyrizon is an Israeli biotech company developing protective sprays against viruses and allergens. The chart shows how investors view its innovative platform and its potential for creating a new class of preventative treatments.
Market to book capitalization ratio for the market as a whole
Polyrizon develops preventative medications in the form of sprays that create a protective barrier on mucous membranes. The company's value is determined by its unique technology and patents. This chart shows how investors value innovative pharmaceutical approaches aimed at preventing, not just treating, disease.
Debts of the company, segment and market as a whole
PLRZ - Company debts Polyrizon Ltd
Polyrizon, an Israeli biotech company developing protective gels to prevent infections, is in the early stages of raising seed funding to conduct preclinical and early clinical trials. This timeline reflects the startup's funding needs as it seeks to prove its scientific concept.
Market segment debts - Specialized pharma
Polyrizon is an Israeli biotech company developing protective gels and sprays to prevent viruses and allergens from entering the body through mucous membranes. This chart shows how the company is funding its early-stage R&D and clinical trials for its innovative preventative platform.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Polyrizon Ltd
Polyrizon develops protective gels and sprays for the nose and mouth that create a barrier against viruses and allergens. Bringing new medical devices to market requires expenditures on clinical research, manufacturing, and marketing. This chart shows how the company uses debt to finance the commercialization of its innovative product line.
Market segment debt to market segment book capitalization - Specialized pharma
Polyrizon develops preventative medications in the form of nasal and oral sprays to protect against viruses and allergens. This is an innovative approach to prevention. This chart shows how the biotech startup finances its research. It compares its debt structure to the overall financial landscape of the biotech sector.
Debt to book value of all companies in the market
Polyrizon Ltd develops protective gels for the nose and other mucous membranes that can prevent the penetration of viruses and allergens. Early-stage biotechnology requires significant investment. How dependent is the company on debt? This chart of total debt in the economy provides context for assessing the risks of its financial model.
P/E of the company, segment and market as a whole
P/E - Polyrizon Ltd
Polyrizon is an Israeli biotech company developing protective gels for the nose and mouth to prevent viruses and allergens. This chart shows how investors rate its preventative approach. The rating depends on clinical data and the commercial potential of its products.
P/E of the market segment - Specialized pharma
Polyrizon Ltd. is an Israeli biomedical company developing preventative products (such as nasal sprays) based on its platform, which create a protective barrier against viruses and allergens. This chart illustrates the average valuation in the specialty pharmaceuticals sector, where investors evaluate the potential of innovative preventative products.
P/E of the market as a whole
Polyrizon Ltd. is an Israeli biomedical company developing protective gels that create a barrier on mucous membranes to prevent the penetration of viruses and allergens. This chart reflects the overall sentiment in the healthcare sector. It helps us understand whether PLRZ is valued as an innovative company with a unique preventative technology or whether its value moves in line with the overall market.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Polyrizon Ltd
Polyrizon Ltd is a biomedical company developing protective gels and sprays for the nose and mouth that create a barrier against viruses and allergens. The company's future depends on the success of its products. This chart shows how the market assesses the commercial potential of this preventative technology and the future demand for similar protective products.
%20P%2FE%20Polyrizon%20Ltd&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Polyrizon-Ltd&v=1772537139978 "Chart of the company's future (projected) P/E Polyrizon Ltd")
Future (projected) P/E of the market segment - Specialized pharma
Polyrizon Ltd develops protective gels and sprays that create a barrier on mucous membranes to prevent the penetration of viruses and allergens. The chart reflects future profit forecasts for the sector. It helps understand the market's confidence in this preventative approach and its commercial potential in a post-pandemic world.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Specialized-pharma&v=1772537140073 "Future (projected) P/E graph of the market segment - Specialized pharma")
Future (projected) P/E of the market as a whole
Polyrizon Ltd. is an Israeli biotech company developing protective nasal gels that can prevent viral and allergic infections. This innovative approach to prevention is a key component of the company's strategy. This market sentiment chart shows how much investors believe in the potential of new preventative medical products.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772537140124 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Polyrizon Ltd
Polyrizon Ltd. is an Israeli biotechnology company developing protective gels and sprays to prevent the penetration of viruses and allergens through mucous membranes. Financial indicators reflect R&D expenses. This chart shows investments in the development of a new class of prophylactic products.
Profit of companies in the market segment - Specialized pharma
Polyrizon Ltd. is an Israeli biotechnology company that develops protective gels and sprays that create a barrier on mucous membranes to prevent the penetration of viruses and allergens. This graph shows the overall profitability of the specialty pharmaceutical sector, where preventative, rather than curative, approaches could capture an important market niche.
Overall market profit
Polyrizon Ltd is a biomedical company developing protective gels to prevent viruses and allergens from entering the body. The demand for such preventative measures may increase during epidemics, but is generally driven by public health concerns. This market is weakly linked to general economic cycles, as shown in this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Polyrizon Ltd
Polyrizon Ltd develops polymer-based protective gels and sprays to prevent the penetration of viruses and allergens through mucous membranes. Future revenue depends on the commercialization of this preventative technology. This chart reflects analysts' expectations regarding the potential of its platform in the fight against infectious and allergic diseases.
%20profit%20of%20the%20company%20Polyrizon%20Ltd&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Polyrizon-Ltd&v=1772537140339 "Graph of future (projected) profit of the company Polyrizon Ltd")
Future (predicted) profit of companies in the market segment - Specialized pharma
Polyrizon develops protective gels and sprays that create a barrier on the mucous membranes of the nose and mouth to prevent the penetration of viruses and allergens. This technology offers a new approach to disease prevention. This graph shows profitability expectations for the specialty pharmaceutical sector, helping to evaluate Polyrizon's innovations.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Specialized-pharma&v=1772537140406 "Graph of future (predicted) profits of companies in a market segment - Specialized pharma")
Future (predicted) profit of the market as a whole
Polyrizon Ltd is a biomedical company developing protective gels to prevent viruses and allergens from entering the body. Its success depends on the commercialization and market acceptance of its products. This economic outlook affects overall consumer spending on health and wellness products.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772537140524 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Polyrizon Ltd
Polyrizon develops protective gels and sprays to prevent viruses and allergens from entering the body through mucous membranes. Revenue is minimal during the development stage. This chart reflects investor valuation of its innovative preventative platform.
P/S market segment - Specialized pharma
Polyrizon is developing a patented platform for creating protective gels and sprays that can prevent viruses and allergens from penetrating through the mucous membranes of the nose and mouth. This approach could revolutionize respiratory disease prevention. This chart shows the average revenue estimate for the sector, helping to assess the potential of this innovation.
P/S of the market as a whole
Polyrizon Ltd. is an Israeli biotech company developing protective gels and sprays to prevent the penetration of viruses and allergens through mucous membranes. This chart helps us understand that the valuation of such early-stage companies is based on the potential of their preventative platform, not on current sales.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Polyrizon Ltd
Polyrizon Ltd is developing a platform for creating protective gels and sprays that can prevent the penetration of viruses and allergens through mucous membranes. Estimating future revenue is important for such an innovative company. It reflects investor expectations for the commercialization of its products and the growing demand for preventative measures in a post-pandemic world.
%20P%2FS%20Polyrizon%20Ltd&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Polyrizon-Ltd&v=1772537140716 "The graph of the company's future (projected) P/S Polyrizon Ltd")
Future (projected) P/S of the market segment - Specialized pharma
Polyrizon Ltd develops protective biological gels that create a barrier on mucous membranes to prevent the penetration of viruses and allergens. This chart reflects how investors view the company's future earnings relative to the pharmaceutical sector. It demonstrates the market's confidence in its innovative preventative approach and the potential of its products for the over-the-counter market.
%20P%2FS%20market%20segment%20graph%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Specialized-pharma&v=1772537140792 "Future (projected) P/S market segment graph - Specialized pharma")
Future (projected) P/S of the market as a whole
Polyrizon develops protective gels and sprays that create a barrier on mucous membranes to prevent viral and allergic reactions. The company's success depends on demonstrating the effectiveness and commercialization of this concept. This graph of investor expectations reflects their interest in new approaches to preventive medicine.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772537140858 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Polyrizon Ltd
This chart shows the financial performance of Polyrizon Ltd., an Israeli biotechnology company developing protective gels to prevent the penetration of viruses and allergens through mucous membranes. Being in the development stage, the company may not have commercial revenue.
Sales of companies in the market segment - Specialized pharma
Polyrizon Ltd. is an Israeli biotechnology company developing protective gels to prevent the penetration of viruses and allergens through mucous membranes. Being in the development stage, it does not yet have revenue. Its future revenue will depend on the successful commercialization of this preventative technology.
Overall market sales
Polyrizon Ltd. is an Israeli biotechnology company developing protective gels to prevent the penetration of viruses and allergens through mucous membranes. The company offers an innovative approach to prevention. This general economic outlook does not affect the fundamental need for protection against disease, which is Polyrizon's primary driver.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Polyrizon Ltd
Polyrizon Ltd is a biopharmaceutical company developing protective gels that create a barrier on mucous membranes to prevent the penetration of viruses and allergens. Future revenue depends on the commercialization of this preventative technology. This chart reflects analyst expectations for potential demand for new methods of protection against respiratory infections.
%20sales%20of%20the%20company%20Polyrizon%20Ltd&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Polyrizon-Ltd&v=1772537141239 "Schedule of future (projected) sales of the company Polyrizon Ltd")
Future (projected) sales of companies in the market segment - Specialized pharma
Polyrizon Ltd develops polymer-based protective gels and sprays to prevent the penetration of allergens and viruses. This chart shows the forecast for the specialized pharmaceutical market. Is demand for preventative over-the-counter products growing? This reflects the overall consumer trend toward preventative health care.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Specialized-pharma&v=1772537141243 "Schedule of future (projected) sales of companies in the market segment - Specialized pharma")
Future (projected) sales of the market as a whole
Polyrizon Ltd develops medical products, likely for protection against allergens or viruses. Demand for such preventative measures may be stable, especially after the pandemic. However, this timeframe still impacts consumers' willingness to spend money on over-the-counter health products, especially if they are not covered by insurance.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772537141397 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Polyrizon Ltd
Polyrizon Ltd is a biopharmaceutical company developing protective gels and sprays to prevent the penetration of viruses and allergens through mucous membranes. This chart reflects its financial performance during the development stage. Profitability is a future goal and will depend on the success of its prophylactic platform and the receipt of marketing approvals for its products.
Market segment marginality - Specialized pharma
Polyrizon Ltd. is a biomedical company developing protective gels to prevent viruses and allergens from entering the body through mucous membranes. This chart reflects its financial position at the development stage, where profitability depends on the successful commercialization of its prophylactic platform.
Market marginality as a whole
Polyrizon Ltd, as its name suggests, develops biopharmaceutical products, possibly polymer-based. The success of such companies depends on scientific innovation and the ability to bring it to market. This overall return chart reflects the investment climate, which determines how easy it is for early-stage companies to raise capital.
Employees in the company, segment and market as a whole
Number of employees in the company Polyrizon Ltd
Polyrizon is an Israeli biotech company developing protective gels and sprays to prevent the penetration of viruses and allergens through mucous membranes. Its small staff of scientists is its greatest asset. This graph shows the early-stage team working to commercialize its innovative preventative platform.
Share of the company's employees Polyrizon Ltd within the market segment - Specialized pharma
Polyrizon Ltd develops protective gels for the nose and mouth that create a barrier against viruses and allergens. The development and production of such biomedical products requires teams of chemists and biologists. This chart shows the company's market share, reflecting the scale of its R&D activities and production potential in preventive medicine.
Number of employees in the market segment - Specialized pharma
Polyrizon Ltd develops protective gels for the nose and mouth that create a barrier against viruses and allergens. This chart shows employment in the specialty pharmaceuticals sector. Polyrizon's preventative approach could offer a new way to protect against respiratory infections, complementing vaccines and masks.
Number of employees in the market as a whole
Polyrizon develops biogels for protection against viruses and allergens. This is an innovative approach to disease prevention. The company's growth depends on scientific advances and the acceptance of its products. This chart shows the overall picture, and Polyrizon is an example of a biotech company working to create entirely new categories of health products and developing the scientific talent to do so.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Polyrizon Ltd (PLRZ)
Polyrizon is an Israeli biotech company developing a hydrogel-based platform for creating barriers (for example, in the nose) against allergens and viruses. This chart shows how the market values their IP. It reflects the market value per scientist, which is a measure of the value of their unique delivery and protection platform.
%20of%20the%20company%20Polyrizon%20Ltd%20(PLRZ)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Polyrizon-Ltd-PLRZ&v=1772537141720 "Chart of market capitalization per employee (in thousands of dollars) of the company Polyrizon Ltd (PLRZ)")
Market capitalization per employee (in thousands of dollars) in the market segment - Specialized pharma
Polyrizon (PLRZ) develops biological gels to protect against viruses and allergens by creating a barrier on mucous membranes. In the biotech industry, this characteristic reflects the innovative nature of its approach. The high capitalization per employee suggests that their preventative technology has the potential to become a new standard of protection against respiratory infections.
%20by%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Specialized-pharma&v=1772537141837 "Market capitalization per employee (in thousands of dollars) by market segment - Specialized pharma")
Market capitalization per employee (in thousands of dollars) for the overall market
Polyrizon develops biological gels for protection against viruses and allergens. The company's value is based on the potential of its unique preventative platform. The chart shows a high valuation per employee, as the market sees strong demand for new methods of protection against respiratory diseases, especially after the pandemic.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772537141902 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Polyrizon Ltd (PLRZ)
Polyrizon is a biotech company developing a platform for creating protective barriers (e.g., nasal sprays) against viruses and allergens. It is an early-stage R&D company. This graph shows the investment phase. The loss per employee means that each scientist is a cost center working on product development.
%20Chart%20Polyrizon%20Ltd%20(PLRZ)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Polyrizon-Ltd-PLRZ&v=1772537141911 "Company Profit Per Employee (in thousands of dollars) Chart Polyrizon Ltd (PLRZ)")
Profit per employee (in thousands of dollars) in the market segment - Specialized pharma
Polyrizon Ltd. is an Israeli biotech company developing preventative nasal sprays for allergies and viruses. In consumer healthcare, efficiency per employee depends on the speed of product introduction. The graph shows the financial return per team, which is an indicator of the commercial potential of their platform.
%20in%20the%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Specialized-pharma&v=1772537141931 "Chart of profit per employee (in thousands of dollars) in the market segment - Specialized pharma")
Profit per employee (in thousands of dollars) for the market as a whole
Polyrizon Ltd. is an Israeli biotech company developing protective gels (the Capture platform) to prevent the penetration of viruses (COVID, influenza) and allergens through mucous membranes. This is an R&D company. This chart, showing average market efficiency, helps to understand the contrast with R&D companies, where capital is invested in research.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772537141944 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Polyrizon Ltd (PLRZ)
Polyrizon Ltd develops protective gels to prevent viruses and allergens from entering the body. During the commercialization phase, this graph will show market demand. Increased revenue per employee will indicate that their innovative preventative product is finding a consumer, monetizing years of scientific research.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Polyrizon-Ltd-PLRZ&v=1772537141996 "Sales chart per company employee Polyrizon Ltd (PLRZ)")
Sales per employee in the market segment - Specialized pharma
Polyrizon Ltd. is an Israeli early-stage (preclinical) biotech company developing a platform (hydrogels) for creating protective barriers (e.g., a nasal spray) against allergens and viruses. They have no commercial revenue. This chart, showing the average output in the sector, serves as a barometer of PLRZ's R&D staffing costs.
Sales per employee for the market as a whole
Polyrizon (PLRZ) is a biotech company developing a platform for creating protective barriers (e.g., nasal sprays) against allergens and viruses. Currently, their business is focused on R&D. This chart reflects their pre-commercial phase: the company is investing in research and has no sales revenue.
Short shares by company, segment and market as a whole
Shares shorted by company Polyrizon Ltd (PLRZ)
Polyrizon (PLRZ) is an Israeli biotech company developing protective sprays (for the nose and eyes) to prevent allergies and infections. This chart shows the volume of bearish bets. Shorts may reflect doubts about the clinical effectiveness of this barrier protection technology or its widespread adoption.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Polyrizon-Ltd-PLRZ&v=1772537142092 "Short Shares Chart for the Company Polyrizon Ltd (PLRZ)")
Shares shorted by market segment - Specialized pharma
Polyrizon (PLRZ) is an Israeli biotech company developing a spray-based platform for protection against allergens and viruses by creating a barrier on mucous membranes. This chart aggregates short positions in the biotech sector. It reflects investor skepticism about new, unproven preventative technologies.
Shares shorted by the overall market
Polyrizon is a biotech company developing gel traps (for example, for allergies and viruses). It's an early-stage R&D project. This chart reflects the overall market pessimism. When investors are fearful, they don't buy "scientific hypotheses." They see an R&D company without revenue and prefer to cash out.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Polyrizon Ltd (PLRZ)
Polyrizon develops protective nasal sprays (biogels) to block viruses and allergens. This technology has become "hot" during the pandemic. This indicator measures the "temperature" of demand. It "heats up" during disease outbreaks and "cools down" during calm periods, reflecting the news environment.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Polyrizon-Ltd-PLRZ&v=1772537142263 "RSI 14 indicator chart for the company's stock Polyrizon Ltd (PLRZ)")
RSI 14 Market Segment - Specialized pharma
Polyrizon (PLRZ) is an Israeli biotech company developing "bio-shield"—nasal sprays and gels designed to protect against allergens and viruses. This chart tracks the overall sentiment in the specialty pharmaceuticals sector. It helps investors understand whether PLRZ's performance reflects their technology or whether the entire biotech sector is overheated or oversold.
RSI 14 for the overall market
For Polyrizon (PLRZ), a biotech company, this chart is a lifeline showing capital availability. During periods of market euphoria, investors are willing to generously fund risky but promising R&D projects. During periods of panic, the money supply is turned off, and companies burning through cash risk running out of funds.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast PLRZ (Polyrizon Ltd)
Polyrizon is an Israeli biotech company. It develops nasal sprays that create a protective "bio-gel" in the nose, blocking viruses (flu, COVID) and allergens. This chart shows the speculative average price target from analysts, based on their belief in the commercial potential of this preventative R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-PLRZ-Polyrizon-Ltd&v=1772537142448 "A chart showing analyst consensus forecasts for the expected stock price. PLRZ (Polyrizon Ltd)")
The difference between the consensus estimate and the actual stock price PLRZ (Polyrizon Ltd)
Polyrizon is an Israeli biotech company developing nasal sprays. Their technology creates a protective "bio-gel" in the nose to prevent allergies and viruses. This chart shows how much the current share price differs from the "fair" value predicted by analysts. It reflects their faith in this R&D platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-PLRZ-Polyrizon-Ltd&v=1772537142590 "A chart showing the difference between the consensus forecast and the actual stock price. PLRZ (Polyrizon Ltd)")
Analyst consensus forecast for stock prices by market segment - Specialized pharma
Polyrizon (PLRZ) is an Israeli biotech company developing a "bioshield" (gel) for the nose and eyes that promises to protect against viruses (COVID, influenza) and allergens. This chart shows general expectations for the specialty pharmaceutical sector. It reflects whether experts believe there will be demand for "preventative" over-the-counter medications.
Analysts' consensus forecast for the overall market share price
Polyrizon is an Israeli biotech company developing nasal sprays (gels) that create a protective barrier against allergens and viruses. This chart reflects the overall "risk appetite" in the market. For Polyrizon, a company with an innovative delivery platform, overall market optimism (risk appetite) is critical for attracting capital for R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Polyrizon Ltd
Polyrizon is an early-stage Israeli R&D company. Their signature product is a bioadhesive (sticky) R&D platform that creates a protective barrier (gel) for mucous membranes (nose, eyes) to protect against allergens and viruses. This chart is a pure indicator of their R&D. It doesn't reflect revenue, but rather a speculative estimate of their (very risky) pipeline and their chances of success.
AKIMA Market Segment Index - Specialized pharma
Polyrizon (PLRZ) is an Israeli biotech company creating a liquid mask. They are developing bio-gels (the Capture platform) for the nose and eyes that create a protective barrier, capturing viruses (flu, COVID) and allergens before they enter the body. This chart shows the average index for the segment, which helps assess the success of this preventative strategy.
The AKIM Index for the overall market
Polyrizon is a biotech company developing biological gels for protecting mucous membranes from viruses and allergens (nasal spray). This chart, reflecting the market average, provides a macro backdrop. It helps assess how this niche product stacks up against overall economic trends.
